SCHEMBL3754482

SCHEMBL3754482

COC(=O)c1cc2nc(OC)ccc2[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 3/20 0.47
KDM4E B2RXH2 5/20 0.44
ALDH1A1 P00352 5/20 0.44
SIRT2 Q8IXJ6 1/20 0.43
SIRT1 Q96EB6 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.42
HPGD P15428 3/20 0.42
RAB9A P51151 3/20 0.42
LMNA P02545 3/20 0.42
NPC1 O15118 2/20 0.42
HTT P42858 2/20 0.42
CYP1A2 P05177 1/20 0.41
PDGFRB P09619 1/20 0.41
PDGFRA P16234 1/20 0.41
MTNR1A P48039 2/20 0.40
MTNR1B P49286 2/20 0.40
RHEB Q15382 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2107849 0.86 PIN1 (0.47) KDM4EALDH1A1SIRT2SIRT1HPGD
SCHEMBL30310720 0.86 PIN1 (0.47) KDM4EALDH1A1SIRT2SIRT1HPGD
SCHEMBL2109109 0.86 RAB9A (0.60) KDM4EALDH1A1L3MBTL1HPGDRAB9A
SCHEMBL24112624 0.85 ALOX15 (0.47) KDM4EALDH1A1SIRT2SIRT1RAB9A
SCHEMBL4034495 0.85 NNMT (0.46) ALDH1A1SIRT2SIRT1CYP1A2PDGFRB
SCHEMBL30310722 0.85 NNMT (0.46) ALDH1A1SIRT2SIRT1CYP1A2PDGFRB
SCHEMBL24019773 0.83 ALOX15 (0.51) KDM4EALDH1A1SIRT2SIRT1L3MBTL1
SCHEMBL9974594 0.82 XDH (0.47) XDHKDM4EALDH1A1L3MBTL1HPGD
SCHEMBL34471351 0.81 XDH (0.46) XDHKDM4EALDH1A1L3MBTL1HPGD
SCHEMBL5716780 0.80 MEN1 (0.60) ALDH1A1HPGDRAB9ALMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using EXELIXIS, INC. (US) 2010-12-02 US disclosed
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using EXELIXIS, INC. (US) 2010-12-02 US disclosed
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using EXELIXIS, INC. (US) 2010-12-02 US disclosed
WO-2010118208-A1 BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER EXELIXIS, INC. (US) 2010-10-14 WO disclosed
WO-2010118208-A1 BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER EXELIXIS, INC. (US) 2010-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305093-A1 Inhibitors of mTOR and Methods of Making and Using MTOR, RICTOR, RPTOR XDH 3614/4885KDM4E 718/4885ALDH1A1 3391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.